Nyctea Technologies is a biopharmaceutical technology company founded in 2020 by Gustav Ferrand-Drake del Castillo and Professor Andreas Dahlin at Chalmers University of Technology. The company specializes in electronically controlled biomolecule purification systems designed to enhance biopharmaceutical manufacturing. Their innovative approach replaces traditional chromatography resins with electrode-based systems, allowing for dynamic and digitalized purification processes.

The core technology includes electrode filters that bind and release biomolecules such as antibodies and vaccines on demand. This method aims to significantly reduce purification costs and minimize environmental impact by decreasing chemical and water usage. Nyctea Technologies collaborates with biopharmaceutical companies, including a partnership with AstraZeneca, to optimize purification workflows and promote sustainable manufacturing practices. Their mission is to commercialize these purification systems and develop fully automated platforms for all stages of biopharmaceutical production.